According to incomplete statistics from Insight,Last week (August 18 to August 24), there were 26 disclosed financing events in the global health and wellness sector, with a total amount exceeding 900 million US dollars.。

Last week in innovative drug financing, cell and gene therapies were relatively active.

According to the news on August 18,Gene Therapy Company Kriya Therapeutics Secures $313 Million in Financing, becoming one of the largest potential financings in the global biopharmaceutical field this year.The company currently has nine R&D pipelines, covering the central nervous system, metabolic health, and ophthalmology fields, with two projects having entered clinical development.Kriya Therapeutics has also expanded its R&D capabilities through strategic acquisitions in recent years, acquiring Redpin Therapeutics in 2022 to obtain a candidate drug for the treatment of epilepsy and trigeminal neuralgia, and acquiring Tramontane Therapeutics in 2023 to gain an intramuscular gene therapy for non-alcoholic steatohepatitis (NASH).

In the field of anti-tumor,Anocca Secures Approximately $46 Million in Financing to Advance Early Clinical Trials of Non-Viral Gene-Edited TCR-T Cell Therapy VIDAR-1. This therapy targets the oncogenic driver mutations of KRAS and is mainly used to treat pancreatic ductal adenocarcinoma (PDAC).

In the field of regenerative medicine,Innovacell Secures Over 7.3 Billion Yen in Series D Financing to Advance R&D and Commercialization of Its Core Product ICEF15ICEF15 is a cell therapy product based on the patient's own myoblasts, designed to restore muscle function through injection and fundamentally treat fecal incontinence. Innovacell's research focuses on repairing sphincter and pelvic floor muscle dysfunction using regenerative medicine technologies to address fecal and urinary incontinence caused by aging, childbirth, or other factors.

In addition, companies in other fields of innovative drugs, such as small nucleic acid drug research and development and FAK inhibitor research and development, have also received financing.

Vivatides Therapeutics Completes Multi-Million Dollar Seed Financing Round, Mainly for the Development of its Preclinical Extrahepatic Targeted Small Nucleic Acid Platform and PipelineIn recent years, small nucleic acid drugs have developed rapidly in disease treatment. However, commercially available products are mostly concentrated in the liver-targeting field, and non-liver targeting delivery still faces technical bottlenecks. Vivatides Therapeutics was founded in 2025. With its self-developed non-liver delivery technology platform, the company focuses on targeted delivery to non-liver tissues, aiming to meet unmet medical needs.

Ying's Biotech Completes Over $34 Million Series C Financing, Aiming to Address Treatment Resistance Caused by Tumor Defense SystemsThe company, based on in-depth research into the FAK target mechanism and related pathways, has developed a pipeline layout with different targets, mechanisms, and drug combinations for multiple types of tumors, and several clinical trials are currently underway.

Readers, please star ⭐Chuangjianhui to receive updates第一时间.

Disclaimer: This article is for information exchange purposes only. The views expressed in the article do not represent the position of WuXi AppTec, nor does it mean that WuXi AppTec supports or opposes the views mentioned. This article is not a recommendation for treatment plans. For guidance on treatment options, please visit a正规 hospital.

Copyright Statement: Welcome to share with friends circle, unauthorized media or institutions are prohibited from reprinting/copying in any form to other platforms. For reprint authorization, please contact"InnoView"Contact us through the WeChat Official Account comments.

More Data Content Recommendations

Click "InSee", Sharing Chuangjian Hui Health New Trends